| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
25,790,000 |
| Market
Cap: |
10.15(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3936 - $0.3936 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for people suffering from rare and debilitating diseases. Co.'s initial focus is in the field of ophthalmology, where it has wholly owned clinical-stage programs in X-linked retinitis pigmentosa and achromatopsia, and an optogenetics program. Co.'s preclinical pipeline includes a program in dry age-related macular degeneration, two programs targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis, and a program in otology through its collaboration with Otonomy, Inc.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
12,064 |
| Total Sell Value |
$0 |
$0 |
$0 |
$9,626 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Feinsod Matthew |
Interim Chief Medical Officer |
• – – |
2018-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,000 |
29,648 |
|
- |
|
| Feinsod Matthew |
Interim Chief Medical Officer |
• – – |
2017-12-11 |
4 |
D |
$3.75 |
$12,731 |
D/D |
(3,395) |
24,253 |
|
- |
|
| Feinsod Matthew |
Interim Chief Medical Officer |
• – – |
2017-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
27,648 |
|
- |
|
| Feinsod Matthew |
Interim Chief Medical OfficerO |
• – – |
2017-09-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,648 |
|
- |
|
| Oronsky Arnold L |
Director |
– • – |
2017-04-24 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,688 |
11,208 |
|
- |
|
| Maravic Magovcevic Ivana |
Director |
– • – |
2016-11-16 |
4 |
B |
$9.63 |
$28,875 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-11-01 |
4 |
AS |
$7.05 |
$7,052 |
D/D |
(1,000) |
20,400 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-10-19 |
4/A |
OE |
$0.35 |
$3,500 |
D/D |
10,000 |
21,400 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-10-19 |
4 |
OE |
$0.35 |
$350 |
D/D |
1,000 |
12,400 |
|
- |
|
| Shearman Mark S |
Chief Scientific Officer |
• – – |
2016-09-22 |
4 |
B |
$8.87 |
$26,602 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Potter Stephen W |
See Remarks |
• – – |
2016-09-20 |
4 |
B |
$8.69 |
$3,476 |
D/D |
400 |
1,400 |
2.66 |
- |
|
| Bullock Lawrence E |
Chief Financial Officer |
• – – |
2016-09-19 |
4 |
B |
$8.75 |
$87,500 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Potter Stephen W |
See Remarks |
• – – |
2016-09-16 |
4 |
B |
$8.97 |
$8,970 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
| Washer Susan B. |
See Remarks |
• • – |
2016-08-29 |
4 |
OE |
$3.50 |
$18,648 |
D/D |
5,328 |
20,328 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-08-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
11,400 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-05-25 |
4 |
OE |
$3.50 |
$7,000 |
D/D |
2,000 |
11,900 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2016-05-11 |
4 |
OE |
$3.50 |
$14,000 |
D/D |
4,000 |
9,900 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2015-12-21 |
5 |
GD |
$0.00 |
$0 |
D/D |
900 |
11,900 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2015-12-16 |
5 |
GD |
$0.00 |
$0 |
D/D |
477 |
11,900 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2015-03-09 |
5 |
OE |
$0.35 |
$875 |
D/D |
2,500 |
7,277 |
|
- |
|
| Glaxosmithkline Plc |
Former 10% Owner |
– – – |
2015-02-23 |
4 |
S |
$22.00 |
$11,069,602 |
I/I |
(503,150) |
1,436,448 |
|
- |
|
| Chulay Jeffrey D. |
VP and Chief Medical Officer |
• – – |
2015-01-29 |
5 |
OE |
$0.35 |
$875 |
D/D |
2,500 |
7,277 |
|
- |
|
| Menichella Daniel L |
V.P. & Chief Business Officer |
• – – |
2015-01-23 |
4 |
S |
$24.90 |
$49,700 |
D/D |
(1,996) |
0 |
|
- |
|
| Menichella Daniel L |
V.P. & Chief Business Officer |
• – – |
2015-01-23 |
4 |
OE |
$4.90 |
$9,780 |
D/D |
1,996 |
1,996 |
|
- |
|
| Menichella Daniel L |
V.P. & Chief Business Officer |
• – – |
2014-12-22 |
4 |
S |
$20.83 |
$187,470 |
D/D |
(9,000) |
0 |
|
- |
|
125 Records found
|
|
Page 4 of 5 |
|
|
